BridgeBio is significantly improved its development of a innovative treatment for ATTR-CM, leveraging Attruby. Early patient information suggests promising benefits for patients affected with a severe condition. This https://biotech759888.life3dblog.com/40504040/bridgebio-improves-cardiac-amyloidosis-management-through-the-therapy